死后尸检中阿尔茨海默病病理与血浆pTau217、GFAP和NfL的关联
结果显示pTau217随Thal期和Braak分期升高而升高,GFAP和NfL无此特异性;非AD痴呆中pTau217阳性多为ADNC共病理。
要点
- 血浆pTau217可准确反映脑内ADNC,即便临床诊断为非AD痴呆。
- 非AD痴呆中pTau217阳性不应视为误诊或假阳性,而提示ADNC共病理。
- GFAP和NfL对ADNC缺乏特异性,GFAP在无ADNC者中48%升高。
核心结论
- 血浆pTau217而非GFAP或NfL能准确反映脑内ADNC,即使临床诊断为非AD痴呆。
研究设计与样本
- 采用Meso Scale Discovery S-PLEX免疫分析检测血浆pTau217、GFAP和NfL。
- 用线性回归模型控制年龄、性别和死亡时间,评估生物标志物与ADNC、原发神经病理诊断及非AD共病理的横断面关联。
主要发现
- pTau217随Thal期升高呈阶梯式增加(β=0.61, 95%CI 0.24-0.97 至 β=0.91, 95%CI 0.55-1.27)。
- pTau217随Braak分期升高呈阶梯式增加(β=0.59, 95%CI 0.16-1.01 至 β=0.74, 95%CI 0.33-1.15)。
- 非AD原发诊断者中23% pTau217升高,其中62%有中/高ADNC共病理,其余为临界升高。
- 无ADNC者中48% GFAP升高;pTau217和GFAP在有无脑淀粉样血管病、α-突触核蛋白或TDP-43蛋白病、原发tau病时无差异。
- NfL与ADNC无特异性关联。
关键数值与推荐
- pTau217升高 cutoff 基于ADNC与正常对照的对比定义。
- 非AD原发诊断者中23% pTau217升高,其中62%有中/高ADNC共病理。
- 无ADNC者中48% GFAP升高。
临床怎么用
- 疑似非AD痴呆患者血浆pTau217阳性应视为ADNC共病理证据,而非误诊或假阳性。
- 血浆pTau217可用于反映脑内ADNC,GFAP和NfL对ADNC特异性不足。
局限性
- 样本来自单一中心队列,正常对照无尸检数据。
- 横断面设计,无法推断因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Alzheimer disease (AD) and its related disorders (ADRDs) are characterized by a high frequency of copathologies. We aimed to determine the specificity of plasma pTau217, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) for AD neuropathological change (ADNC) in the presence of common ADRD copathologies. METHODS: pTau217, GFAP, and NfL were measured using S-PLEX immunoassays from Meso Scale Discovery in banked plasma samples from 2 groups of participants in the Massachusetts Alzheimer's Disease Research Center (MADRC) Longitudinal Cohort study: (1) participants spanning the cognitive spectrum, who underwent brain autopsy, and blood collection within 6 years before death, and (2) participants with normal cognition and no neurologic diagnosis during 5 years of follow-up, but no autopsy data (normal controls [NCs]). Cross-sectional associations between biomarker levels and ADNC, primary neuropathologic diagnosis (NPDx1), and presence of non-AD copathologies were evaluated using linear regression models controlling for age, sex, and time to death. RESULTS: One hundred eighty-seven participants with brain autopsy (NPDx1: AD n = 85; other n = 102; mean age: 74.3 years, 38.5% female; interval blood collection-death [mean ± SD]: 2.8 ± 1.6 years) and 67 NC without brain autopsy (mean age: 66.5 years, 71.6% female) were included. pTau217, but not GFAP, levels increased stepwise with increasing Thal phases (β = 0.61; 95% CI [0.24-0.97] to β = 0.91 [0.55-1.27]) and Braak stages (β = 0.59; [0.16-1.01] to β = 0.74 [0.33-1.15]). Although 23% of individuals with a non-AD NPDx1 had increased pTau217 levels using a cutoff defined by the contrast between ADNC and NC, the majority (62%) had intermediate/high ADNC copathology and the remaining pTau217+ individuals had borderline increased levels. By contrast, 48% of individuals without ADNC had increased GFAP levels. pTau217 and GFAP were not different in the presence or absence of cerebral amyloid angiopathy, α-synuclein or TDP-43 proteinopathies, or primary tauopathies. NfL was not specifically associated with ADNC. DISCUSSION: Plasma pTau217, but not GFAP or NfL, levels accurately reflect the presence of ADNC in the brain even in individuals with an NPDx1 of a non-AD dementia. Thus, a positive plasma pTau217 test in an individual with a suspected non-AD dementia should not necessarily be considered a misdiagnosis of the presumed non-AD dementia or as a false positive, but rather as evidence of ADNC copathology.
引用
- Kivisäkk P, Fatima H, Wu CY, et al. Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias. Neurology. 2026. PMID: 41610380. doi:10.1212/WNL.0000000000214351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。